Fiche société
Epicrispr Biotechnologies, Inc.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications1liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| EPI-321The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working? Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321. | Myopathies | Phase 1/2 | À vérifier | United States, Australia, New Zealand | À vérifier |
| EPI-321The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working? Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321. | Myopathies | Phase 1/2 | À vérifier | United States, Australia, New Zealand | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| EPI-321 | Myopathies | Phase 1/2 | NCT06907875 | FSHD — A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
Publications
1| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| EPI-321 | Epigenetic editing approaches maturity: AI-driven precision design, delivery innovation, and the road to clinical translation. | Clinical epigenetics |